SCHEMBL4333115

SCHEMBL4333115

C=CC(N)c1cc2ccccc2[nH]1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AOC3 Q16853 2/20 0.46
ALOX5 P09917 1/20 0.44
LOXL2 Q9Y4K0 1/20 0.42
CYP2A6 P11509 1/20 0.42
CA2 P00918 1/20 0.40
NPC1 O15118 2/20 0.39
RAB9A P51151 2/20 0.39
FLT3 P36888 1/20 0.38
KDM4E B2RXH2 4/20 0.37
MAPT P10636 4/20 0.37
DAO P14920 2/20 0.37
HPGD P15428 2/20 0.37
SRD5A2 P31213 1/20 0.37
HSD17B10 Q99714 1/20 0.37
BRD4 O60885 1/20 0.37
DDO Q99489 1/20 0.37
ALDH1A1 P00352 3/20 0.37
MAPK1 P28482 2/20 0.37
GAA P10253 1/20 0.37
GRIN2D O15399 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Quinoline SCHEMBL27603533 0.86 ALDH1A1 (0.45) AOC3ALOX5NPC1RAB9AKDM4E
SCHEMBL6157427 0.81 CYP2A6 (0.44) AOC3ALOX5LOXL2CYP2A6CA2
SCHEMBL5049788 0.79 AOC3 (0.50) AOC3ALOX5LOXL2CYP2A6CA2
SCHEMBL14532292 0.79 ALOX5 (0.48) AOC3ALOX5LOXL2CYP2A6CA2
SCHEMBL6543889 0.79 ALOX5 (0.44) AOC3ALOX5LOXL2CYP2A6CA2
SCHEMBL30063329 0.79 ALOX5 (0.44) AOC3ALOX5LOXL2CYP2A6CA2
SCHEMBL4382025 0.79 CYP2A6 (0.42) AOC3ALOX5LOXL2CYP2A6CA2
SCHEMBL23468379 0.76 ALOX5 (0.51) AOC3ALOX5LOXL2CYP2A6CA2
SCHEMBL3229357 0.76 ALOX5 (0.55) AOC3ALOX5LOXL2CYP2A6CA2
SCHEMBL4760638 0.75 ALOX5 (0.41) AOC3ALOX5LOXL2CYP2A6CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 180 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117899209-A Vaccination and antibody production platform 德国癌症研究公共权益基金会 2024-04-19 CN claimed
WO-2023150396-A1 DEVICES, METHODS AND KITS FOR DETECTING EXPLOSIVES AND ILLICIT DRUG SUBSTANCES TRACE EYE-D, LLC (US) 2023-08-10 WO claimed
CN-108853509-A The treatment and pharmaceutical composition of depression 浙江大学 2018-11-23 CN claimed
CN-101489548-A Use of cannabinoid receptor agonists as hypothermia inducing drugs for the treatment of ischemia NEUROKEY AS (DK) 2009-07-22 CN claimed
CN-1867332-A Comprising a selective CB1Combination therapy of obesity with antagonists and lipase inhibitors SOLVAY PHARM GMBH (DE) 2006-11-22 CN claimed
CN-1845735-A Novel medical use of selective cb1-receptor antagonists SOLVAY PHARM GMBH (DE) 2006-10-11 CN claimed
CN-1610542-A New use for the treatment of gastroesophageal reflux disease ASTRAZENECA AB (SE) 2005-04-27 CN claimed
WO-2024108201-A2 CANNABIGEROLIC ACID (CBGA) AND CANNABIGEROL (CBG) DERIVED PRODUCTS AND METHODS OF USE Bazelet Health Systems, Inc. (US) 2024-05-23 WO disclosed
CN-113710235-B Oral cannabinoid tablet 诺狄更斯公司 2024-03-29 CN disclosed
CN-117677383-A Combinations of ketone bodies or ketone-forming compounds, analgesics or antioxidants 瑞士凯托股份公司 2024-03-08 CN disclosed
US-20230330115-A1 COMPOSITION COMPRISING COMBINATIONS OF CANNABINOID HOMOLOGUES THCB (TETRAHYDROCANNABUTOL) AND THCP (TETRAHYDROCANNABIPHOROL) Green Sky Creations, LLC (US) 2023-10-19 US disclosed
CN-113329743-B Tableted cannabinoid chewing gum with polyvinyl acetate elastomer plasticizer 诺狄更斯公司 2023-09-05 CN disclosed
WO-2023150396-A1 DEVICES, METHODS AND KITS FOR DETECTING EXPLOSIVES AND ILLICIT DRUG SUBSTANCES TRACE EYE-D, LLC (US) 2023-08-10 WO disclosed
EP-0348341-A2 Aminoalkyl indoles, process for their preparation and pharmaceutical compositions thereof SCHERING AKTIENGESELLSCHAFT (DE) 1989-12-27 EP disclosed
US-4839377-A TREATMENT OF MIGRAINE GLAXO GROUP LIMITED (GB) 1989-06-13 US disclosed
EP-0252404-A2 5-Hydroxy-3-indoleacetic acid fluorescence polarization immunoassay ABBOTT LABORATORIES (US) 1988-01-13 EP disclosed
US-4672067-A 5-substituted 3-aminoalkyl indoles useful in treatment of migraine GLAXO GROUP LIMITED (GB) 1987-06-09 US disclosed
US-4636521-A ANALGESICS GLAXO GROUP LIMITED (GB) 1987-01-13 US disclosed
US-4636521-A ANALGESICS GLAXO GROUP LIMITED (GB) 1987-01-13 US disclosed
US-4374846-A N-Amino alkyl indole compounds compositions containing same, and a method of using same in therapy of disorders of gastrointestinal motility KALI-CHEMIE PHARMA GMBH (DE) 1983-02-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230330115-A1 COMPOSITION COMPRISING COMBINATIONS OF CANNABINOID HOMOLOGUES THCB (TETRAHYDROCANNABUTOL) AND THCP (TETRAHYDROCANNABIPHOROL) CNR2, CNR1, FAAH AOC3 3303/4885ALOX5 1204/4885LOXL2 2504/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.